FDA Red Tape Is Killing Patients and Crushing Small Pharmacies

Why does FDA regulation cost lives?

FDA approval delays prevent patients from accessing therapies that are already saving lives in Europe, Japan, and Israel, while clinical trial requirements add years and billions of dollars to development. The result is fewer treatments, higher prices, and suffering that market-based systems could avoid. Patients deserve better than bureaucratic delay.

The Tufts Center for the Study of Drug Development estimated in 2023 that bringing a single new prescription medicine to market costs more than $2.6 billion and takes over a decade. That price tag includes failed candidates and the administrative burden of satisfying regulators who move at government speed. The FDA's Center for Drug Evaluation and Research approved 50 novel drugs in 2024, a respectable number, but the agency also rejects or stalls countless therapies for patients with terminal illnesses. For someone facing metastatic cancer, a one-year delay can be a death sentence.

Right-to-try laws exist in dozens of states because voters understand that terminal patients should not need a federal permit to save their own lives. Yet the FDA still erects barriers to experimental treatments, compounding pharmacies, and off-label uses that physicians support. Regulators defend this caution by pointing to safety. But caution has a cost measured in coffins. Other developed nations approve drugs faster and often adopt them at lower prices before Americans can fill a prescription.

How do regulations crush small healthcare businesses?

Independent pharmacies, small medical practices, and diagnostic labs face thousands of pages of federal rules, compliance costs, and exclusion from preferred pharmacy networks controlled by large insurers. These burdens push family-owned providers out of the market and reduce patient choice. Big hospitals and pharmacy benefit managers write the rules they can afford to follow.

The Kaiser Family Foundation reports that average annual premiums for employer-sponsored family health coverage reached $25,572 in 2024, with workers contributing thousands more out of pocket. Small businesses, which employ nearly half of American workers, cannot absorb those increases while also paying lawyers and consultants to decode federal mandates. Certificate-of-need laws in 35 states and the District of Columbia require providers to prove community need before adding hospital beds or imaging machines. Established hospitals use those laws to block competitors, not to protect patients.

Pharmacy benefit managers exploit opaque rebate arrangements that independent pharmacies cannot match. Direct and indirect remuneration fees hit small drugstores months after a transaction, making cash flow unpredictable. The Federal Trade Commission has studied these middlemen, but Congress has been slow to act. Meanwhile, rural communities watch their last independent pharmacy close because the regulatory deck is stacked against Main Street.

What would a patient-centered market look like?

A patient-centered market allows off-label communication, right-to-try access, direct primary care, transparent cash prices, and importation of safe drugs from certified foreign suppliers, all of which put decisions back in the hands of patients instead of bureaucrats. Competition would replace monopoly pricing with the discipline of consumer choice. Patients would shop for value the way they shop for everything else.

Direct primary care offers a preview. Patients pay a flat monthly fee for unlimited access to a physician, bypassing insurance paperwork and administrative bloat. Cash prices for imaging and labs are often a fraction of insurance-negotiated rates. Telemedicine and health sharing ministries show that innovation flourishes when Washington steps back. The FDA and state licensing boards should not be allowed to protect incumbents under the guise of quality control.

Drug importation from countries with comparable safety standards, such as Canada and the United Kingdom, would inject price competition into markets currently dominated by patent monopolies. The FDA already inspects foreign facilities and could certify safe suppliers without replicating every domestic trial. Patients should be free to buy approved medicines from certified international pharmacies instead of waiting for a domestic manufacturer to charge the highest price the market will bear.

Can Congress restore medical freedom?

Congress can cap FDA review times, allow reciprocity with trusted foreign regulators, repeal certificate-of-need laws, and bar states from protecting incumbent hospital monopolies through anti-competitive licensing rules. Those changes would expand supply, cut prices, and return control to patients and their doctors. The Constitution never granted federal agencies a monopoly on hope.

Reciprocity means that if regulators in Germany, Switzerland, or Japan approve a therapy, American patients gain access without restarting a decade-long domestic trial. This approach respects science, trusts international partners, and saves lives. Congress could also expand health savings accounts, eliminate the tax bias toward employer-sponsored coverage, and let patients own their insurance policies across state lines. Portability and choice would become real, not slogans.

State legislators should scrap certificate-of-need laws that serve only as moats around hospital empires. The Mercatus Center and other research institutions have documented how these laws reduce hospital capacity, raise prices, and limit rural access. Medical licensing boards should recognize out-of-state telehealth and practitioner credentials where standards are equivalent. Competition is not a threat to quality. It is the engine that produces it.

Freedom works in healthcare the same way it works everywhere else. When patients control the dollars, providers compete for their business, and entrepreneurs can enter markets without permission from entrenched interests, costs fall and outcomes improve. The alternative is more of the same: longer waits, higher bills, and Washington deciding who gets care and when. Americans have tried the regulatory state. They deserve a dose of liberty.